Cargando…
LGG-06. Selumetinib in pediatric patients with non-neurofibromatosis type 1-associated, non-optic pathway (OPG) and non-pilocytic recurrent/progressive low-grade glioma harboring BRAFV600E mutation or BRAF-KIAA1549 fusion: a multicenter prospective Pediatric Brain Tumor Consortium (PBTC) Phase 2 trial
BACKGROUND: A greater understanding of the Ras-MAP kinase pathway in pediatric low-grade glioma (LGG) paired with the availability of selective inhibitors has enhanced the ability to target this pathway with therapeutic intent. METHODS: The PBTC conducted a multi-institutional phase II study (NCT010...
Autores principales: | Fangusaro, Jason, Onar-Thomas, Arzu, Poussaint, Tina Young, Lensing, Shelly, Wu, Shengjie, Ligon, Azra H, Lindeman, Neal, Stewart, Clinton F, Jones, David T W, Pfister, Stefan M, Smiley, Natasha Pillay, Leach, James, Packer, Roger, Vezina, Gilbert, Lenzen, Alicia, Jaju, Alok, Goldman, Stewart, Doyle, Laurence Austin, Smith, Malcolm, Fouladi, Maryam, Dunkel, Ira |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9164871/ http://dx.doi.org/10.1093/neuonc/noac079.322 |
Ejemplares similares
-
LGG-04. A PHASE II RE-TREATMENT STUDY OF SELUMETINIB FOR RECURRENT OR PROGRESSIVE PEDIATRIC LOW-GRADE GLIOMA (pLGG): A PEDIATRIC BRAIN TUMOR CONSORTIUM (PBTC) STUDY
por: Fangusaro, Jason, et al.
Publicado: (2020) -
LGG-53. Evaluation of KIAA-BRAF1549 fusions in pilocytic astrocytoma with clinicopathological correlation
por: Dandapath, Iman, et al.
Publicado: (2022) -
LGG-54. DETECTION OF THE KIAA1549-BRAF FUSION GENE IN CELLS FORMING MICROVASCULAR PROLIFERATIONS IN PILOCYTIC ASTROCYTOMA
por: Yamashita, Shinji, et al.
Publicado: (2020) -
EPCT-02. PBTC-051: FIRST IN PEDIATRICS PHASE 1 STUDY OF CD40 AGONISTIC MONOCLONAL ANTIBODY APX005M IN PEDIATRIC SUBJECTS WITH RECURRENT/REFRACTORY BRAIN TUMORS
por: Lindsay, Holly, et al.
Publicado: (2020) -
Evaluating Focal Areas of Signal Intensity (FASI) in Children with Neurofibromatosis Type-1 (NF1) Treated with Selumetinib on Pediatric Brain Tumor Consortium (PBTC)-029B
por: Pillay-Smiley, Natasha, et al.
Publicado: (2023)